Open Equity
MRKR·

Marker Therapeutics: The Grant Is Bigger Than the Market Cap

Speculative BuyHealthcare / BiotechnologyNano CapPublished November 19, 2026
View Our Thesis ↓

MRKR — 6 Month Price History

Daily OHLC

Executive Summary

Marker Therapeutics (NASDAQ: MRKR) jumped 15.9% to $0.989 in Thursday's pre-market on 406,613 shares — almost 3x its 151,649-share average — after winning a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas, one of 12 awards from 207 applications. The money funds the planned Phase 2 APOLLO study of MT-601 (neldaleucel), its multi-antigen MAR-T cell therapy, in large B-cell lymphoma relapsed after CD19 CAR-T. It lands on $9.4 million of cash (September 30), a disclosed runway into Q2 2027 and a going-concern warning.

The grant exceeds Marker's ≈$16.5 million market cap and nearly doubles its cash — non-dilutive money that reprices a financing orphan as a grant-funded Phase 2 story. Phase 1 APOLLO posted a 66% response rate and 50% complete response in 12 evaluable NHL patients, updated data due this year. Blending 55% funded execution (≈$2.50) against 45% financing stress (≈$0.60) yields our $1.65 target. Speculative Buy.

Business Model & Revenue

Marker is a Houston-based clinical-stage immuno-oncology company built on the multi-antigen recognizing (MAR)-T cell platform, exclusively licensed worldwide from Baylor College of Medicine. Its lead product, MT-601 (neldaleucel), is an autologous T-cell therapy that is not genetically modified: instead of engineering a single-antigen receptor like a CAR-T, Marker selectively expands tumor-specific T cells that recognize up to six antigens upregulated in lymphoma — Survivin, PRAME, WT-1, NY-ESO-1, SSX-2 and MAGEA4 — covering hundreds of epitopes and reducing the antigen-loss escape that drives relapse after CD19-directed therapy. Because the cells are not engineered, management believes manufacturing is simpler and cheaper than engineered approaches; Kincellis, a CDMO, handles technology transfer and cGMP production for APOLLO.

There is no commercial revenue and there may not be for years. The near-term economic model is almost unique among nano-cap biotechs: development funded by competitive non-dilutive awards — CPRIT, NIH/NCI, FDA's orphan-products program and the Department of War — with $2.7 million of grant income recognized in the first nine months of 2026, about 27% of operating expenses. Value inflection comes from clinical data (updated Phase 1 results this year, then the Phase 2 APOLLO readout path in post-CAR-T large B-cell lymphoma), not sales.

If MT-601 advances, the commercial model is a classic orphan indication: relapsed post-CAR-T LBCL is a small, desperate population with poor outcomes and established cell-therapy pricing benchmarks, and multi-antigen targeting would differentiate on escape resistance and manufacturing cost.

Financial Highlights

P&L Trend (no product revenue; grant income offsets spend)

MetricQ3 2026Q3 20259M 20269M 2025
Net loss($1.8M)($2.0M)($6.8M)($10.5M)
Net loss per share($0.10)($0.12)($0.35)($0.75)
Grant income$1.3M$1.2M$2.7M$2.4M

Nine-month R&D expense fell 33% year over year to $6.5 million, mainly on lower clinical-trial spend, while operating cash use totaled $7.6 million. Grant income now covers roughly a quarter of operating expenses.

Balance Sheet (September 30, 2026)

ItemAmount
Cash and equivalents$9.04M
Restricted cash$0.39M
Grant receivable$2.43M
Total current assets$12.50M
Shares outstanding (11/13/26)16,673,127

Non-Dilutive Funding Stack (secured awards)

AwardAmountPurpose
CPRIT Product Development (Nov 2026)$16.2MPhase 2 APOLLO — MT-601 in post-CAR-T LBCL
U.S. Department of War (prior disclosure)$4.2MLymphoma development
FDA Orphan Products (Sept 2026)$2.6MPhase 1 in locally advanced pancreatic cancer
NCI / NIH SBIR (incl. R44CA291521)—Phase 1 APOLLO support

Guidance: No product revenue or financial guidance. Management estimates runway into Q2 2027 absent additional grant receipts; substantial doubt about going concern remains disclosed. Updated APOLLO clinical data expected later this year.

Competitive Landscape

Marker's niche is the salvage slot: patients whose large B-cell lymphoma has already failed CD19 CAR-T. Every competitor below is either the therapy MT-601 follows or the one it must beat for that patient.

  • Gilead Sciences (GILD) — Yescarta/Tecartus: the CD19 CAR-T franchise that defines the frontline-relapsed standard MT-601 follows; also the benchmark for cell-therapy commercial execution.
  • Bristol Myers Squibb (BMY) — Breyanzi: the competing CD19 CAR-T in LBCL; its relapse population is Marker's addressable market.
  • Novartis (NVS) — Kymriah: the third approved CD19 CAR-T; same dynamic — every Kymriah relapse is a potential APOLLO enrollment.
  • Roche (ROG.SW) and AbbVie/Genmab — CD20 bispecifics (Lunsumio/glofitamab class; Epkinly): off-the-shelf T-cell engangers approved or advancing in post-CAR-T relapse; the direct commercial rivals for the same salvage patients, with no manufacturing complexity.
  • Allogeneic CAR-T programs (public and private): donated-cell engineered approaches chasing the same post-CAR-T slot with faster logistics.

Moats:

  1. Multi-antigen recognition — six targets and hundreds of epitopes versus single-antigen CAR-Ts, directly attacking the antigen-loss escape mechanism
  2. Non-genetically-modified manufacturing — simpler and lower-cost production than engineered cells, with a contracted cGMP CDMO already in place
  3. Baylor College of Medicine exclusive worldwide license plus a clinical history of more than 200 patients treated across MAR-T studies
  4. A funding moat no nano-cap peer has: state and federal grant capital — CPRIT, NCI, FDA and the Department of War — that pays for development without touching the share count

Catalysts

  1. Updated APOLLO Phase 1 data — later this year: additional patients and response-durability updates on top of the 66% ORR / 50% CR in 12 evaluable NHL patients, with responses up to 24 months at the prior cutoff

  2. Phase 2 APOLLO initiation in post-CAR-T LBCL: the CPRIT-funded registrational-pathway study in relapsed or refractory large B-cell lymphoma following CD19 CAR-T — the value-defining event

  3. Grant cash conversion through 2027: CPRIT, Department of War ($4.2 million) and FDA ($2.6 million) receipts hitting the balance sheet as qualifying costs are incurred — the mechanism that retires the going-concern warning

  4. FDA-funded pancreatic Phase 1: the $2.6 million orphan-products award supports a Phase 1 in locally advanced unresectable pancreatic cancer; initiation timing was unconfirmed in the Q3 filing, so a start would be incremental news

  5. Data-driven partnership interest: positive updated Phase 1 results would put a cheap, grant-funded, multi-antigen asset in front of the same licensors who have paid up for post-CAR-T assets

Key Risks

  • Going concern — $9.4 million of cash at September 30, disclosed runway into Q2 2027 and substantial doubt about the ability to continue; CPRIT grants reimburse incurred costs rather than arriving as lump sums, and $2.4 million of grant income already sits in receivables, so receipt timing can still force a raise
  • Clinical — the 66% objective response rate and 50% complete response rest on 12 evaluable patients in a single-arm Phase 1; small-n cell-therapy response rates routinely compress as cohorts expand, and Phase 2 APOLLO has not yet started
  • Financing and dilution — any gap between grant receipts and clinical spend forces equity issuance the going-concern language anticipates; the December 2025 private placement with pre-funded warrants shows the path of least resistance is a discounted deal
  • Listing — the stock traded at $0.84-0.99 this week, below the $1.00 Nasdaq minimum bid threshold, exposing it to a deficiency process that historically ends in a reverse split
  • Competitive — post-CAR-T LBCL is being commercialized now by CD20 bispecifics and next-generation CAR-Ts from Gilead, Bristol Myers Squibb, Novartis and Roche; MT-601 must demonstrate differentiation against entrenched off-the-shelf options to win the salvage slot

Our Thesis

The market cap forgot the funding stack. Marker's September 10-Q showed $9.4 million of cash, runway into Q2 2027 and substantial doubt about going concern — a fair reason the stock traded under $1. But since September the company has stacked a $2.6 million FDA orphan-products award on a previously disclosed $4.2 million Department of War lymphoma award, and now a $16.2 million CPRIT grant that survived a 207-application, 12-winner review of science, regulatory strategy, manufacturing and commercial potential. Pro forma cash of ≈$25.6 million against a ≈$16.5 million market cap means the pipeline — MT-601, a non-genetically-modified MAR-T therapy targeting six lymphoma antigens, exclusively licensed worldwide from Baylor College of Medicine — is priced below zero after grant-timing risk.

Our $1.65 target is a scenario blend, not a multiple. At 55%, CPRIT and DoW money funds the Phase 2 APOLLO start in post-CAR-T LBCL and updated Phase 1 data lands this year as promised; a grant-funded nano-cap with $25.6 million of tracked cash and a 66% ORR / 50% CR Phase 1 dataset deserves ≈$2.50, about 1.6x pro forma cash. At 45%, grant receipts lag spend — CPRIT grants reimburse incurred costs rather than arriving as lump sums, and $2.4 million already sits in receivables — forcing the dilution the going-concern language warns about, worth ≈$0.60. Blend: 0.55 × $2.50 + 0.45 × $0.60 ≈ $1.65, a 67% expected return that belongs in the speculative bucket.

Disclaimer: This report is for informational purposes only and does not constitute financial advice. Small-cap, micro-cap, and nano-cap stocks carry significant risk including limited liquidity and higher volatility. Always do your own due diligence before making investment decisions.

Get reports like this delivered free

New small-cap research every week. No paywall, no fluff.